CPIX
CUMBERLAND PHARMACEUTICALS INC
+0.37 (+5.30%)7.35USD40.7K成交股數110M市值–本益比(近四季)2.7股價營收比-18.8%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 8.8M-19% | 9.1M-22% | 13.7M+31% | 8.3M-9% | 10.8M+10% | 11.7M+38% | 10.4M+12% | 9.1M-10% | 9.8M | 8.5M | 9.4M | 10.1M |
| 營業成本 | – | 1.9M | – | 989K | 2.0M | 1.4M | – | 1.3M | 1.7M | 1.6M | – | 1.8M |
| 毛利 | – | 7.2M-30% | – | 7.3M-6% | 8.8M+8% | 10.3M+49% | – | 7.8M-7% | 8.1M | 6.9M | – | 8.3M |
| 毛利率 | – | 78.8% | – | 88.1% | 81.4% | 87.8% | – | 85.4% | 82.6% | 81.5% | – | 82.5% |
| 研發費用 | 772K | 1.5M | – | 1.3M | 837K | 1.3M | – | 1.3M | 1.1M | 1.2M | – | 1.9M |
| 銷售管理費用 | 2.5M | 2.6M | – | 2.6M | 2.7M | 2.5M | – | 2.7M | 2.8M | 2.4M | – | 2.3M |
| 營業利益 | −3.2M+1% | −3.1M-342% | −1.4M-26% | −2.0M+16% | −3.1M+204% | 1.3M-169% | −1.8M-70% | −1.7M-9% | −1.0M | −1.9M | −6.2M | −1.9M |
| 營業利益率 | -35.9% | -34.3% | -10.0% | -23.7% | -28.8% | 11.0% | -17.7% | -18.6% | -10.4% | -22.0% | -66.1% | -18.5% |
| 稅後淨利 | −4.3M+477% | −3.3M-362% | −1.4M-26% | −1.9M+26% | −741K-32% | 1.3M-165% | −1.9M-70% | −1.5M+47% | −1.1M | −1.9M | −6.3M | −1.0M |
| 淨利率 | -48.6% | -36.0% | -10.3% | -23.4% | -6.8% | 10.7% | -18.2% | -17.0% | -11.0% | -22.9% | -67.3% | -10.4% |
| 稀釋 EPS | -0.29+480% | -0.22-375% | -0.09-36% | -0.13+18% | -0.05-38% | 0.08-157% | -0.14-68% | -0.11+57% | -0.08 | -0.14 | -0.44 | -0.07 |
| 稀釋股數 | 15.0M | 15.0M | – | 15.0M | 15.0M | 15.3M | – | 14.1M | 14.1M | 14.1M | – | 14.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 3.9M | 11.0M | 11.4M | 15.2M | 16.1M | 15.1M | 18.0M | 17.5M | 17.3M | 18.5M | 18.3M | 18.5M |
| 應收帳款 | 13.4M | 14.3M | 16.9M | 10.4M | 10.3M | 10.5M | 11.7M | 11.3M | 11.6M | 10.6M | 9.8M | 12.6M |
| 存貨 | 30K | 5.5M | 30K | 2.9M | 3.2M | 4.1M | 4.0M | 4.5M | 4.3M | 4.3M | 4.6M | 8.7M |
| 總資產 | 62.9M | 71.0M | 76.8M | 65.9M | 67.9M | 69.9M | 75.6M | 76.7M | 78.5M | 81.5M | 81.8M | 87.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 45.8M | 49.7M | 52.3M | 40.1M | 40.2M | 41.6M | 53.0M | 52.3M | 52.5M | 54.3M | 52.5M | 52.1M |
| 股東權益 | 17.4M | 21.6M | 24.9M | 26.1M | 28.0M | 28.7M | 22.9M | 24.8M | 26.3M | 27.5M | 29.6M | 36.0M |
| 負債比 | 72.8% | 70.0% | 68.1% | 60.8% | 59.2% | 59.5% | 70.2% | 68.1% | 66.8% | 66.6% | 64.2% | 59.4% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 387K-90% | – | – | – | 3.9M-282% | – | – | – | −2.1M | – | – |
| 資本支出 | – | 0 | – | – | – | 48K | – | – | – | 42K | – | – |
| 自由現金流 | – | 387K-90% | – | – | – | 3.9M-277% | – | – | – | −2.2M | – | – |
| 折舊攤銷 | – | 1.3M | – | – | – | 1.0M | – | – | – | 1.2M | – | – |
| 買回庫藏股 | – | 61K | – | – | – | 246K | – | – | – | 248K | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 4.2% | – | – | – | 32.9% | – | – | – | -25.6% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 4.9M
| 美國以外 | 4.9M | 100.0% | +81.5% |
|---|
產品／服務2025 年度 · 84.4M
| 產品 | 40.4M | 47.9% | +10.6% |
|---|---|---|---|
| Product Sancuso | 11.9M | 14.1% | +32.2% |
| Product Kristalose | 10.5M | 12.5% | -31.2% |
| Product Vibativ | 9.5M | 11.2% | +32.5% |
| Manufactured Product Other | 4.1M | 4.9% | +210.1% |
| Product Other | 4.1M | 4.9% | +210.1% |
| Product Talicia | 3.3M | 3.9% | – |
| Product Acetadote | 508K | 0.6% | +174.4% |
| Product Redi Trex | 11K | 0.0% | -87.4% |
| Product Caldolor 小計 | 4.7M | 5.5% | -6.0% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 44.5M | +17.6% | −2.8M | -6.4% | -0.19 | 4.8M |
| FY2024 | 37.9M | -4.3% | −6.5M | -17.1% | -0.46 | −679K |
| FY2023 | 39.6M | -5.9% | −6.3M | -15.9% | -0.44 | 5.8M |
| FY2022 | 42.0M | +19.9% | −5.6M | -13.3% | -0.38 | 8.4M |
| FY2021 | 35.0M | -2.2% | −3.5M | -10.0% | -0.24 | 6.2M |
| FY2020 | 35.8M | +10.6% | −3.3M | -9.3% | -0.22 | 5.3M |
| FY2019 | 32.4M | +12.5% | −3.5M | -10.9% | -0.23 | 2.8M |
| FY2018 | 28.8M | – | −7.0M | -24.2% | -0.45 | 2.7M |